Renal cell carcinoma (RCC)-derived gangliosides reduce IL-2 and IFN-γ expression (77) and increase apoptosis in T cells through NF-κB inhibition by reducing RelA(p65), p50, and antiapoptotic protein Bcl-xL (78). This evidence concerns the gene IL2 and renal cell carcinoma.